Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA | Optometry Times - Clinical News

Published on January 4, 2026
K8 is a member of a new class of inflammasome-inhibiting drugs called kamuvudines.
Continue reading on website
Other news

NCX 470 advances toward US, China NDA submissions for NCX 470 | Optometry Times - Clinical News

January 3, 2026
NCX 470 is Nicox’s lead dual-mechanism bimatoprost eye drop for lowering IOP in open-angle glaucoma or ocular hypertension.

Study maps thermal dynamics of glaucoma laser treatments | Optometry Times - Clinical News

January 4, 2026
The study evaluated thermal dynamics associated with CW-TSCPC and TLT using MicroPulse technology, such as temperature peak, exposure duration, and thermal spread in a simulated ciliary body using computer modeling.